Table 4b.

Characteristics of patients with virologic failure at study enrollment and re-suppression at follow-up

			Study enrollment
	Routine clinical VL testing				Predicted phenotypic resistance		Routine clinical VL testing		Study follow-up
Patient	N months before enrollment	VL(ART used)*	VL(copies/mL)	Mutations	NNRTI	NRTI	N months after study enrollment	VL(copies/mL)	N months of last VL test after study enrollment	VL(copies/mL)
					H: EFV; NVP	H: 3TC
2	6	535 (1a)	2 680	D67N+K101H+V106M+M184V+G190A+F227L		S:d4T	6	982	10	≤400
					H: EFV; NVP	H: 3TC
22	2	42,187 (1a)	1 280	K103N+V106M+M184V		S:d4T	6	64,312	9	≤400
					H: EFV; NVP	H: 3TC
26	7	≤400 (1a)	1 370	K103N+M184V		S: d4T	6	≤400	9	≤400
	Treatment was interrupted for 10				H: EFV; NVP
27	months	NA(1a)	178 000	K103N		S: 3TC; d4T	NA	NA	5	≤400
					H: EFV; NVP
28	6	191 (1a)	56 500	K103N		S: 3TC; d4T	4	≤400	7	≤400
					H: EFV; NVP
29	3	19,653 (1a)	42 800	K103N		S: 3TC; d4T	3	≤400	10	≤400
					S: EFV; NVP
33	7	≤400 (1b)	882 000	Wild type		S: 3TC; d4T	NA	NA	6	≤400
					S: EFV; NVP
34	2	20,758 (1b)	1 450	Wild type		S: 3TC; d4T	NA	NA	4	≤400
					S: EFV; NVP
37	7	≤400 (1a)	312 000	Wild type		S: 3TC; d4T	3	≤400	8	≤400
41	6	≤400 (1a)	1 060	Not amplifiable	---	---	6	≤400	9	≤400
42	4	≤400 (1a)	557	Not amplifiable	---	--	1	≤400	8	≤400
43	4	≤400 (1a)	66 800	Not amplifiable	---	--	3	≤400	7	≤400

NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI; VL, virus load (copies/mL); TB, tuberculosis; DRM, drug resistance mutations; Line 1a, Efavirenz (EFV) + Lamivudine (3TC) + Stavudine (d4T); Line 1b, Nevirapine (NVP) + 3TC + d4T; Colors for predicted phenotypic resistance were: White if susceptible (S) or potentially-low (PL); Light gray if low (L) or intermediate (I) and dark gray if highly (H) resistant.